BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 27941982)

  • 1. Overexpression of a Mycobacterium ulcerans Ag85B-EsxH Fusion Protein in Recombinant BCG Improves Experimental Buruli Ulcer Vaccine Efficacy.
    Hart BE; Lee S
    PLoS Negl Trop Dis; 2016 Dec; 10(12):e0005229. PubMed ID: 27941982
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recombinant BCG Expressing Mycobacterium ulcerans Ag85A Imparts Enhanced Protection against Experimental Buruli ulcer.
    Hart BE; Hale LP; Lee S
    PLoS Negl Trop Dis; 2015 Sep; 9(9):e0004046. PubMed ID: 26393347
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of the vaccine potential of plasmid DNA encoding nine mycolactone polyketide synthase domains in Mycobacterium ulcerans infected mice.
    Roupie V; Pidot SJ; Einarsdottir T; Van Den Poel C; Jurion F; Stinear TP; Huygen K
    PLoS Negl Trop Dis; 2014; 8(1):e2604. PubMed ID: 24392169
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prime-boost vaccination with Bacillus Calmette Guerin and a recombinant adenovirus co-expressing CFP10, ESAT6, Ag85A and Ag85B of Mycobacterium tuberculosis induces robust antigen-specific immune responses in mice.
    Li W; Li M; Deng G; Zhao L; Liu X; Wang Y
    Mol Med Rep; 2015 Aug; 12(2):3073-80. PubMed ID: 25962477
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of Immunogenicity and Protective Efficacy Elicited by Mycobacterium bovis BCG Overexpressing Ag85A Protein against Mycobacterium tuberculosis Aerosol Infection.
    Xu ZZ; Chen X; Hu T; Meng C; Wang XB; Rao Y; Zhang XM; Yin YL; Pan ZM; Jiao XA
    Front Cell Infect Microbiol; 2016; 6():3. PubMed ID: 26858942
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protective efficacy of a DNA vaccine encoding antigen 85A from Mycobacterium bovis BCG against Buruli ulcer.
    Tanghe A; Content J; Van Vooren JP; Portaels F; Huygen K
    Infect Immun; 2001 Sep; 69(9):5403-11. PubMed ID: 11500410
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recombinant BCG coexpressing Ag85B, ESAT-6 and Rv3620c elicits specific Th1 immune responses in C57BL/6 mice.
    Yang E; Lu Y; Xu Y; Liang Q; Wang C; Wang H; Shen H
    Microb Pathog; 2014; 69-70():53-9. PubMed ID: 24726737
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vaccine-Specific Immune Responses against Mycobacterium ulcerans Infection in a Low-Dose Murine Challenge Model.
    Mangas KM; Buultjens AH; Porter JL; Baines SL; Marion E; Marsollier L; Tobias NJ; Pidot SJ; Quinn KM; Price DJ; Kedzierska K; Zeng W; Jackson DC; Chua BY; Stinear TP
    Infect Immun; 2020 Feb; 88(3):. PubMed ID: 31818964
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vaccination with the Surface Proteins MUL_2232 and MUL_3720 of Mycobacterium ulcerans Induces Antibodies but Fails to Provide Protection against Buruli Ulcer.
    Bolz M; Bénard A; Dreyer AM; Kerber S; Vettiger A; Oehlmann W; Singh M; Duthie MS; Pluschke G
    PLoS Negl Trop Dis; 2016 Feb; 10(2):e0004431. PubMed ID: 26849213
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunogenicity and protective efficacy conferred by a novel recombinant Mycobacterium bovis bacillus Calmette-Guérin strain expressing interleukin-12p70 of human cytokine and Ag85A of Mycobacterium tuberculosis fusion protein.
    Deng YH; He HY; Zhang FJ
    Scand J Immunol; 2013 Dec; 78(6):497-506. PubMed ID: 24283772
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cellular immunity confers transient protection in experimental Buruli ulcer following BCG or mycolactone-negative Mycobacterium ulcerans vaccination.
    Fraga AG; Martins TG; Torrado E; Huygen K; Portaels F; Silva MT; Castro AG; Pedrosa J
    PLoS One; 2012; 7(3):e33406. PubMed ID: 22413022
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improved protective efficacy of a species-specific DNA vaccine encoding mycolyl-transferase Ag85A from Mycobacterium ulcerans by homologous protein boosting.
    Tanghe A; Dangy JP; Pluschke G; Huygen K
    PLoS Negl Trop Dis; 2008 Mar; 2(3):e199. PubMed ID: 18350112
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    Jia Q; Masleša-Galić S; Nava S; Horwitz MA
    mBio; 2022 Jun; 13(3):e0068722. PubMed ID: 35642945
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structural basis and designing of peptide vaccine using PE-PGRS family protein of Mycobacterium ulcerans-An integrated vaccinomics approach.
    Nain Z; Karim MM; Sen MK; Adhikari UK
    Mol Immunol; 2020 Apr; 120():146-163. PubMed ID: 32126449
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fusion protein Ag85B-MPT64(190-198)-Mtb8.4 has higher immunogenicity than Ag85B with capacity to boost BCG-primed immunity against Mycobacterium tuberculosis in mice.
    Luo Y; Wang B; Hu L; Yu H; Da Z; Jiang W; Song N; Qie Y; Wang H; Tang Z; Xian Q; Zhang Y; Zhu B
    Vaccine; 2009 Oct; 27(44):6179-85. PubMed ID: 19712772
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A live attenuated BCG vaccine overexpressing multistage antigens Ag85B and HspX provides superior protection against Mycobacterium tuberculosis infection.
    Yuan X; Teng X; Jing Y; Ma J; Tian M; Yu Q; Zhou L; Wang R; Wang W; Li L; Fan X
    Appl Microbiol Biotechnol; 2015 Dec; 99(24):10587-95. PubMed ID: 26363555
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Priming but not boosting with plasmid DNA encoding mycolyl-transferase Ag85A from Mycobacterium tuberculosis increases the survival time of Mycobacterium bovis BCG vaccinated mice against low dose intravenous challenge with M. tuberculosis H37Rv.
    Romano M; D'Souza S; Adnet PY; Laali R; Jurion F; Palfliet K; Huygen K
    Vaccine; 2006 Apr; 24(16):3353-64. PubMed ID: 16488518
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The safety and immunogenicity of an adenovirus type 35-vectored TB vaccine in HIV-infected, BCG-vaccinated adults with CD4(+) T cell counts >350 cells/mm(3).
    Churchyard GJ; Snowden MA; Hokey D; Dheenadhayalan V; McClain JB; Douoguih M; Pau MG; Sadoff J; Landry B
    Vaccine; 2015 Apr; 33(15):1890-6. PubMed ID: 25698492
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Heterologous boosting with recombinant VSV-846 in BCG-primed mice confers improved protection against Mycobacterium infection.
    Zhang M; Dong C; Xiong S
    Hum Vaccin Immunother; 2017 Apr; 13(4):816-822. PubMed ID: 27960596
    [TBL] [Abstract][Full Text] [Related]  

  • 20. rBCG induces strong antigen-specific T cell responses in rhesus macaques in a prime-boost setting with an adenovirus 35 tuberculosis vaccine vector.
    Magalhaes I; Sizemore DR; Ahmed RK; Mueller S; Wehlin L; Scanga C; Weichold F; Schirru G; Pau MG; Goudsmit J; Kühlmann-Berenzon S; Spångberg M; Andersson J; Gaines H; Thorstensson R; Skeiky YA; Sadoff J; Maeurer M
    PLoS One; 2008; 3(11):e3790. PubMed ID: 19023426
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.